Merck & Co Inc (MRK.N)
46.32USD
1 Jul 2013
$-0.13 (-0.28%)
$46.45
$46.22
$46.85
$46.22
3,685,840
4,139,014
$50.16
$40.10
MRK.N
About
Overall
| Beta: | 0.58 |
| Market Cap (Mil.): | $139,868.41 |
| Shares Outstanding (Mil.): | 3,019.61 |
| Dividend: | 0.43 |
| Yield (%): | 3.71 |
Financials
| MRK.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.61 | 32.92 | 33.02 |
| EPS (TTM): | 1.96 | -- | -- |
| ROI: | 7.18 | 19.76 | 19.07 |
| ROE: | 11.16 | 20.57 | 20.00 |
FDA rejects Merck insomnia drug, seeks lower-dose
- U.S. health regulators have rejected Merck & Co's new insomnia drug application but opened the door to approving a lower-dose version of the medication, the company said on Monday.
FDA rejects Merck's insomnia drug
- Merck & Co Inc said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues.
EMERGING MARKETS-Shares eye 3rd day of gains after 5-week dive
LONDON, June 28 - Emerging stock markets looked set to gain more than 1 percent for the third day running on Friday, helped by more lenient credit conditions in China after a sell-off on the prospect of reduced U.S. monetary stimulus.
Deals of the day -- mergers and acquisitions
June 27 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:
UPDATE 1-Aspen adds $1 bln deal with Merck to drug acquisition drive
JOHANNESBURG, June 27 - South Africa's Aspen Pharmacare said on Thursday it would acquire drugs and a manufacturing business from U.S. drugmaker Merck in a $1 billion deal to bolster its presence in Europe, Latin America and Asia.
South Africa's Aspen in $1 billion deal with Merck
JOHANNESBURG - Aspen Pharmacare said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia.
South Africa's Aspen in $1 bln deal with Merck
JOHANNESBURG, June 27 - Aspen Pharmacare said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia.
BRIEF-South Africa's Aspen in $1 bln deal with Merck
JOHANNESBURG, June 27 - Aspen Pharmacare Holdings Ltd : * Signing of an agreement to acquire api manufacturing facilities * Agreement on an option to acquire a portfolio of products from msd * Agreement with Merck for the acquisition of an active pharmaceutical
Merck & Co wins injunction against Indian firm over diabetes drugs
MUMBAI - MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India.
Merck & Co wins injunction against Indian firm over diabetes drugs
MUMBAI, June 25 - MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $86.63 | +0.77 |
| Pfizer Inc. (PFE.N) | $27.78 | -0.23 |
| Abbott Laboratories (ABT.N) | $35.03 | +0.15 |
| Eli Lilly & Co. (LLY.N) | $50.16 | +1.04 |
| Bristol Myers Squibb Co. (BMY.N) | $44.82 | +0.13 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (MRK). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
